Bioxcel Therapeutics, Inc.

Bioxcel Therapeutics, Inc. company information, Employees & Contact Information

Biopharmaceutical company developing transformative medicines in neuroscience utilizing artificial intelligence
Looking for a particular Bioxcel Therapeutics, Inc. employee's phone or email?

Bioxcel Therapeutics, Inc. Questions

News

BioXcel Therapeutics to Ring Nasdaq Closing Bell on October - GlobeNewswire

BioXcel Therapeutics to Ring Nasdaq Closing Bell on October GlobeNewswire

BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies - Yahoo Finance

BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies Yahoo Finance

BioXcel Therapeutics Submits Pre-Supplemental New Drug - GlobeNewswire

BioXcel Therapeutics Submits Pre-Supplemental New Drug GlobeNewswire

BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025 - GlobeNewswire

BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025 GlobeNewswire

BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates - GlobeNewswire

BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates GlobeNewswire

BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI® - GlobeNewswire

BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI® GlobeNewswire

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewswire

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia GlobeNewswire

BioXcel Therapeutics Announces Positive FDA Pre-sNDA - GlobeNewswire

BioXcel Therapeutics Announces Positive FDA Pre-sNDA GlobeNewswire

BioXcel Therapeutics Announces $14 Million Registered Direct Offering - GlobeNewswire

BioXcel Therapeutics Announces $14 Million Registered Direct Offering GlobeNewswire

BioXcel Therapeutics Announces Reverse Stock Split - GlobeNewswire

BioXcel Therapeutics Announces Reverse Stock Split GlobeNewswire

BioXcel Therapeutics Announces FDA Closed its Inspection of - GlobeNewswire

BioXcel Therapeutics Announces FDA Closed its Inspection of GlobeNewswire

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024 - Yahoo Finance

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024 Yahoo Finance

BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia - Yahoo Finance

BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia Yahoo Finance

BioXcel Therapeutics Announces Termination of Proposed Public Offering - Yahoo Finance

BioXcel Therapeutics Announces Termination of Proposed Public Offering Yahoo Finance

BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results - Stock Titan

BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results Stock Titan

BioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment Authority - GlobeNewswire

BioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment Authority GlobeNewswire

Top Bioxcel Therapeutics, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant